ERBB2 and endometrial cancer: The most important marker commonly reported is HER2, that is overexpressed in some subset cases of breast, ovarian, gastric, colorectal, pancreatic and endometrial cancers, targeted by Trastuzumab [70], but in the majority of cases the lack of specific markers make promising target therapies non-exploitable.